Stay updated with breaking news from Arthur Suckow. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The acquisition of DTx Pharma by drug giant Novartis includes the potential for an additional $500 million payout depending on reaching certain pre-determined milestones
This interview highlights Dr Arthur Suckow’s insights into how his team uses RNA therapeutics to treat rare diseases.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Print DTx Pharma, a 15-employee San Diego biotechnology company pursuing a platform for creating RNA-based therapies to treat genetic drivers of rare diseases, said Monday that it has raised $100 million in Series B round of financing. The early stage company, which previously raised $10.6 million in a Series A round in January 2020, is pursuing potential treatments in ophthalmology and for neuromuscular diseases initially. According to DTx Pharma’s website, its most advanced program in the eye arena targets a disease called retinitis pigmentosa, which is often inherited. It anticipates ini...